MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/15622975.2021.1878427

Медицинская библиотека · The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry · 2021

Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants.

Eap C B, Gründer G, Baumann P, Ansermot N, Conca A, Corruble E, Crettol S, Dahl M L, de Leon J, Greiner C, Howes O, Kim E, Lanzenberger R, Meyer J H, Moessner R, Mulder H, Müller D J, Reis M, Riederer P, Ruhe H G, Spigset O, Spina E, Stegman B, Steimer W, Stingl J, Suzen S, Uchida H, Unterecker S, Vandenberghe F, Hiemke C

СтатьяОбзорПеревод в очереди

Аннотация

Objectives

More than 40 drugs are available to treat affective disorders. Individual selection of the optimal drug and dose is required to attain the highest possible efficacy and acceptable tolerability for every patient.

Methods

This review, which includes more than 500 articles selected by 30 experts, combines relevant knowledge on studies investigating the pharmacokinetics, pharmacodynamics and pharmacogenetics of 33 antidepressant drugs and of 4 drugs approved for augmentation in cases of insufficient response to antidepressant monotherapy. Such studies typically measure drug concentrations in blood (i.e. therapeutic drug monitoring) and genotype relevant genetic polymorphisms of enzymes, transporters or receptors involved in drug metabolism or mechanism of action. Imaging studies, primarily positron emission tomography that relates drug concentrations in blood and radioligand binding, are considered to quantify target structure occupancy by the antidepressant drugs in vivo.

Results

Evidence is given that in vivo imaging, therapeutic drug monitoring and genotyping and/or phenotyping of drug metabolising enzymes should be an integral part in the development of any new antidepressant drug.

Conclusions

To guide antidepressant drug therapy in everyday practice, there are multiple indications such as uncertain adherence, polypharmacy, nonresponse and/or adverse reactions under therapeutically recommended doses, where therapeutic drug monitoring and cytochrome P450 genotyping and/or phenotyping should be applied as valid tools of precision medicine.

Для цитирования: Eap C B, Gründer G, Baumann P, Ansermot N, Conca A, Corruble E, Crettol S, Dahl M L, de Leon J, Greiner C, Howes O, Kim E, Lanzenberger R, Meyer J H, Moessner R, Mulder H, Müller D J, Reis M, Riederer P, Ruhe H G, Spigset O, Spina E, Stegman B, Steimer W, Stingl J, Suzen S, Uchida H, Unterecker S, Vandenberghe F, Hiemke C. Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants.. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry. 2021. DOI: 10.1080/15622975.2021.1878427.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.